Clinical and Experimental Pharmacology Group
Job Ref: MI/14/53
Fixed term funding until September 2016
Salary in the range of £22,100 – £37,100 dependent upon qualifications and experience
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), an Institute of The University of Manchester (www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org), the largest independent cancer research organisation in the world. We are adjacent to The Christie NHS Foundation Trust (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes spans a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. The Institute has outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry. We are situated in Manchester, England, a vibrant and dynamic city that is surrounded by beautiful countryside and has excellent transport links both nationally and internationally.
The overall goal of the Clinical and Experimental Pharmacology Group (CEP) led by Prof Caroline Dive is to develop repeatable blood tests that facilitate the optimisation of cancer patient treatment – personalised medicine. In this regard, CEP is an acknowledged world leader in the study of circulating tumour cells (CTCs) in lung cancer patients. Our translational research is conducted in partnership with Thoracic Medical Oncologist Dr Fiona Blackhall at the adjacent The Christie NHS Foundation Trust and with the newly established CRUK Lung Cancer Centre of Excellence. Under the guidance of CEP Deputy Group Leader Dr Ged Brady, we are now able to isolate single CTCs from patients’ blood samples and derive their genomic profiles utilising next generation sequencing (Hodgkinson et al Nature Medicine, June 2014). We will for the first time using advanced molecular analysis define CTC heterogeneity and examine differences in CTC genomic profiles of small cell lung cancer (SCLC) patients who are sensitive or resistant to chemotherapy, an approach that will ultimately lead to biomarker signatures for therapy selection.
This is an exciting opportunity funded by Silicon Biosystems, whose innovative technology platform underpins this project. The successful candidate will have an MSc in Computer Science or related numerical discipline (or significant relevant experience) and the ability to analyze single cell genomics data. Knowledge of collaborating with the Pharmaceutical Industry will confer an advantage.
Bioinformatics guidance will be provided at The Cancer Research UK Manchester Institute by Dr Crispin Miller and his Computational Biology Group.
Informal enquiries can be addressed to Dr Ged Brady via email: firstname.lastname@example.org.
To apply for this position please visit our website: www.cruk.manchester.ac.uk
For applicants who are unable to download this information from our website, please contact HR department on 0161 446 3231, email: email@example.com to have this information sent by post.
The deadline for receipt of applications is: 28 October 2014.
Opening For Bioinformatician : Manchester